Recent developments in the area of macrolide antibiotics

Bibliography

• JONES RN, LOW DE, PFALLER MA: Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn. Microbiol. Infect. Dis. (1999) 33:101–112.
   PubMed Web of Science ®Google Scholar
• HEROLD BC, IMMERGLUCK LC, MARANAN MC et al.: Community-acquired methicillin-resistant Staphylo-coccus aureus in children with no identified predis-posing risk. J. Am. Med. Assoc. (1998) 279:593–598.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION:Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. J. Am. Med. Assoc. (1999) 282:1123–1125.
   PubMed Web of Science ®Google Scholar
• KHURSHID MA, CHOU T, CAREY R, LARSEN R, CONOVER, BORNSTEIN SL: Staphylococcus aureus with reduced susceptibility to vancomycin. Morb. Mortal. Weekly Rep. (2000) 48:1165–1167.
   PubMedGoogle Scholar
• JACOBS MR, FELMINGHAN D, APPELBAUM PC, THE ALEXANDER PROJECT GROUP: Penicillin and macrolide resistance in 2675 isolates of Streptococcus pneumo-niae from 15 countries on five continents. 39th ICAAC San Francisco, USA (1999) Abst. 1044.
   Google Scholar
• DOERN GV, BRUEGGEMANN AB, HUYNH H, WINGERT E:Antimicrobial resistance with Streptococcus pneumo-niae in the United States, 1997-98. Emerg. Infect. Dis. (1999) 5:757–765.
   PubMed Web of Science ®Google Scholar
• BRYSKIER A: New research in macrolides and ketolides 1997. Exp. Opin. Invest. Drugs (1999) 8:1171–1194.
   PubMedGoogle Scholar
• •A current review on ketolides, covering roughly the same time frame as present manuscript.
   Google Scholar
• CHU DTW: Recent progress in novel macrolides, quinolones and 2-pyridones to overcome bacterial resistance. Med. Res. Rev. (1999) 19:497–520.
   PubMedGoogle Scholar
• LECLERCQ R, COURVALIN P: Streptogramins: an answer to antibiotic resistance in Gram-positive bacteria. Lancet (1998) 352:591–592.
   PubMedGoogle Scholar
• BARBACHYN MR, BRICKNER SJ, GADWOOD RC et al: Design, synthesis and evaluation of novel oxazolidi-none antibacterial agents active against multidrug- bacteria. Adv. Exp. Med. Biol. (1998) 456:219–238.
   PubMedGoogle Scholar
• BRYSKIER A: Novelties in the field of macrolides. Exp.. Invest. Drugs (1997) 6:1697–1709.
   PubMedGoogle Scholar
• •Good historical perspective on how ketolides evolved.
   Google Scholar
• KIRST H: Recent developments with macrolide antibi-otics. Exp. Opin. Ther. Patents (1998) 8:111–120.
   Web of Science ®Google Scholar
• FINES M, LECLERCQ R: New antibiotics in development in the macrolide, lincosamide and streptogramin group. Curr. Opin. Anti-infective Invest. Drugs (1999) 1:443–452.
   Google Scholar
• KATZ L, MCDANIEL R: Novel macrolides through engineering. Med. Res. Rev. (1999) 19:543–558.
   PubMed Web of Science ®Google Scholar
• •Recommended reading for those interested in macrolide combinatorial biosynthesis.
   Google Scholar
• CHU DTW: Recent developments in macrolides and ketolides. Curr. Opin. Microbiol (1999) 2:467–474.
   PubMedGoogle Scholar
• SUTCLIFFE J, MUELLER J, UTT E: Antibiotic resistance mechanisms of bacterial pathogens. In: Manual of Industrial Microbiology and Biotechnology. Demain AL, Davies JE (Eds.), ASM Press, Washington DC, USA (1999):759–788.
   Google Scholar
• WEISBLUM B: Macrolide resistance. Drug Resist. Updates (1998) 1:29–41.
   PubMed Web of Science ®Google Scholar
• WEISBLUM B: Resistance to macrolide-lincosamide-streptogramin antibiotics. In: Gram-positive pathogens. Fischetti V (Ed.), ASM Press, Washington DC, USA (2000):682–698.
   Google Scholar
• •Latest in a series of excellent reviews.
   Google Scholar
• CAO Z, HAMMOND R, PRATT S et al.: Mechanism ofaction for novel ketolide - ABT-773. 39th ICAAC. San Francisco, USA (1999) Abstract F–2135.
   Google Scholar
• HANSEN LH, MAUVAIS P, DOUTHWAITE S: The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol. Microbic)]. (1999) 31:623–631.
   PubMed Web of Science ®Google Scholar
• •Excellent study to define ketolide binding site.
   Google Scholar
• XIONG L, SHAH S, MAUVAIS P, MANKIN AS: A ketolide mutation in domain II of 23S rRNA reveals the proximity of hairpin 35 to the peptidyl transferase centre. Mol. Microbic)]. (1999) 31:633–639.
   PubMed Web of Science ®Google Scholar
• •Excellent read of ketolide binding and resistance at the level of the ribosome.
   Google Scholar
• CHAMPNEY WS: Macrolide antibiotic inhibition of 50Sribosomal subunit formation in bacterial cells. Recent Res. Devel. in Antimicrob. Agents and Chemother. (1999) 3:39–58.
   Google Scholar
• BERTHO G, GHARBI-BENAROUS J, DELAFORGE M et al.: Conformational analysis of ketolide, conformations of RU 004 in solution and bound to bacterial ribosomes. J. Med. Chem. (1998) 41:3373–3386.
   PubMed Web of Science ®Google Scholar
• ••NMR studies of the interaction between HMR-3004 andribosomes.
   Google Scholar
• DOUTHWAITE S, MAUVAIS P, CHAMPNEY WS, BRYSKIER: Structure-activity relationship of the ketolide telithromycin (HMR 3647). Proceedings of the Fifth International Conference on the Macrolides, Azalides,, Ketolides and Oxazolidinones. Seville, Spain (2000) Abstract 02.02.
   Google Scholar
• DOUTHWAITE S, MAUVAIS P, HANSEN LH: The C11,12-carbamate side chain of the ketolide antimicro-bial telithroimycin (HMR 3647) enhances binding to both MLS-sensitive and -resistant ribosomes. Proceed-ings of the Fifth International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones. Seville, Spain (2000) Abstract 02.01.
   Google Scholar
• ZHONG P, CAO Z, HAMMOND R et al: Induction ofribosome methylation in M1S-resistant Streptococcus pneumoniae by macrolides and ketolides. Microb. Drug Resist. (1999) 5:183–188.
   PubMed Web of Science ®Google Scholar
• SUTCLIFFE J, BRENNAN L, DUIGNAN J et al: Certainpneumococcal strains containing an Ermb methylase display heterotypic resistance to ketolides. 38th ICAAC. San Diego, USA (1998) Abstract C–37.
   Google Scholar
• YU L, PETROS AM, SCHNUCHEL A et al.: Solutionstructure of an rRNA methyltransferase (ErmAM) that confers macrolide-lincosamide-streptogramin antibi-otic resistance. Nature Struct. Biol. (1997) 4:483–489.
   PubMedGoogle Scholar
• BONNEFOY A, GIRARD AM, AGOURIDAS C, CHANTOT JF:Ketolides lack inducibility properties of MLS(B) resistance phenotype. J. Antimicrob. Chemother. (1997) 40:85–90.
   PubMed Web of Science ®Google Scholar
• SUTCLIFFE J: Macrolide resistance in gram-positivepathogens. State-of-the-Art- Minilecturer in Symposium on Macrolide Resistance: Another Emerging Resistance at 37th ICAAC. Toronto, Canada (September 30, 1997).
   Google Scholar
• ROSATO A, VICARINI H, LECLERCQ R: Inducible orconstitutive expression of resistance in clinical isolates of streptococci and enterococci cross-resistant to erythromycin and lincomycin. J. Antimi-crob. Chemother. (1999) 43:559–562.
   PubMedGoogle Scholar
• NASH KA, INDERLIED CB: Genetic basis of macrolideresistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob. Agents Chemother. (1995) 39:2625–2630.
   PubMed Web of Science ®Google Scholar
• METER A, KIRSCHNER P, SPRINGER B et al.: Identificationof mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob. Agents Chemother. (1994) 38:381–384.
   PubMedGoogle Scholar
• VERSALOVIC J, SHORTRIDGE D, KIBLER K et al.:Mutations in 23S rRNA are associated with clarithro-mycin resistance in Helicobacter pylori. Antimicrob. Agents Chemother. (1996) 40:477–480.
   PubMed Web of Science ®Google Scholar
• KARLSSON M, FELLSTROM C, HELDTANDER MU, JOHANSSON KE, FRANKLIN A: Genetic basis of macrolide and lincosamide resistance in Bra chyspira (Serpulina) hyodysenteriae. FEMS Microbiol. Lett. (1999) 172:255–260.
   PubMed Web of Science ®Google Scholar
• HULTEN K, GIBREEL A, SKOLD O, ENGSTRAND L: Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. Antimicrob. Agents Chemother. (1997) 41:2550–2553.
   PubMedGoogle Scholar
• ROSS JI, EADY EA, COVE JH et al: Clinical resistance to erythromycin and clindamycin in cutaneous propionibacteria isolated from acne patients is associ-ated with mutations in 23S rRNA. Antimicrob. Agents Chemother. (1997) 41:1162–1165.
   PubMed Web of Science ®Google Scholar
• ROSS JI, EADY EA, COVE JH, RATYAL AH, CUNLIFFE WJ: Resistance to erythromycin and clindamycin in cutaneous propionibacteria is associated with mutations in 23S rRNA. Dermatology(1998) 196:69–70.
   PubMed Web of Science ®Google Scholar
• TAYLOR DE, GE Z, PURYCH D, LO T, HIRATSUKA K: Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob. Agents Chemother. (1997) 41:2621–2628.
   PubMed Web of Science ®Google Scholar
• STONE GG, SHORTRIDGE D, VERSALOVIC J et al.: A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimi-crob. Agents Chemother. (1997) 41:712–714.
   PubMedGoogle Scholar
• WALLACE RJ, JR., METER A, BROWN BA et al.: Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob. Agents Chemother. (1996) 40:1676–1681.
   Google Scholar
• TAIT-KAMRADT A, DAVIES T, BRENNAN L et al: Two newmechanisms of resistance to macrolides in clinical strains of Streptococcus pneumoniae. 39th ICAAC. San Francisco, USA (1999) Abstract LB–8.
   Google Scholar
• TAIT-KAMRADT A, DAVIES T, CRONAN M et al.: Mutations in 23S rRNA and L4 ribosomal protein account for resistance in pneumococcal strains selected in vitro by macrolide passage. 39th ICAAC. San Francisco, USA (1999) Abstract C–842.
   Google Scholar
• TENSON T, DEBLASIO A, MANKIN A: A functional peptide encoded in the Escherichia coli 23S rRNA. Proc. Natl. Acad. Sci. USA (1996) 93:5641–5646.
   PubMed Web of Science ®Google Scholar
• TENSON T, XIONG L, KLOSS P, MANKIN AS: Erythro-mycin resistance peptides selected from random peptide libraries. J. Biol. Chem. (1997) 272:17425–17430.
   PubMed Web of Science ®Google Scholar
• NOGUCHI N, EMURA A, MATSUYAMA H et al: Nucleotide sequence and characterization of erythromycin resistance determinant that encodes macrolide 2'-phosphotransferase I in Escherichia coli. Antimi-crob. Agents Chemother. (1995) 39:2359–2363.
   PubMedGoogle Scholar
• NOGUCHI N, KATAYAMA J, O'HARA K: Cloning and nucleotide sequence of the mphB gene for macrolide 2'- phosphotransferase II in Escherichia coif FEMS Microbiol. Lett. (1996) 144:197–202.
   Google Scholar
• OUNISSI H, COURVALIN P: Nucleotide sequence of the gene ereA encoding the erythromycin esterase in Escherichia coll. Gene (1985) 35:271–278.
   PubMed Web of Science ®Google Scholar
• ARTHUR M, AUTISSIER D, COURVALIN P: Analysis of the nucleotide sequence of the ereB gene encoding the erythromycin esterase Type II. Nucleic Acids Res. (1986) 14:4987–4999.
   PubMed Web of Science ®Google Scholar
• ROBERTS MC, SUTCLIFFE J, COURVALIN P et al.:Nomenclature for macrolide and macrolide streptogramin B resistance determi-nants. Antimicrob. Agents Chemother. (1999) 43:2823–2830.
   PubMed Web of Science ®Google Scholar
• •A must for aficionados of macrolide resistance determinants.
   Google Scholar
• CHENG J, GREBE T, WONDRACK L, COURVALIN P, SUTCLIFFE J. :Characterization of genes involved in erythromycin resistance in a clinical strain of Staphy-lococcus aureus. 39th ICAAC. San Francisco, USA (1999) Abstract C–837.
   Google Scholar
• MATSUOKA M, ENDOU K, KOBAYASHI H, INOUE M, NAKAJIMA Y: A plasmid that encodes three genes for resistance to macrolide antibiotics in Staphylococcus aureus. FEMS Microbiol. Lett. (1998) 167:221–227.
   PubMed Web of Science ®Google Scholar
• WONDRACK L, MASSA M, YANG By, SUTCLIFFE J: Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides. Antimicrob. Agents Chemother. (1996) 40:992–998.
   PubMed Web of Science ®Google Scholar
• SUTCLIFFE J: Resistance to macrolides mediated byefflux mechanisms. Curr. Opin. Invest. Drugs (1999) 1:403–412.
   Google Scholar
• ROSS JI, EADY EA, COVE JH et al: Inducible erythro-mycin resistance in staphylococci is encoded by a member of the ATP-binding transport super-gene family. Mot. Microbiol. (1990) 4:1207–1214.
   PubMed Web of Science ®Google Scholar
• PORTILLO A, RUIZ-LARREA F, ZATAZAGA M et al: Macrolide resistance genes in Enterococcus spp. 39th ICAAC. San Francisco, USA (1999) Abstract C–1226.
   Google Scholar
• CLANCY J, PETITPAS J, DIB-HAJJ F et al: Molecular cloning and functional analysis of a novel macrolide-resistance determinant, mefA, from Streptococcus pyogenes. Mot. Microbiol. (1996) 22:867–879.
   PubMed Web of Science ®Google Scholar
• TAIT-KAMRADT A, CLANCY J, CRONAN M et al.: mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae. Antimicrob. Agents Chemother. (1997) 41:2251–2255.
   PubMed Web of Science ®Google Scholar
• PORTILLO A, ALONSO A, RUIZ-LARREA F et al: Erythro-mycin resistance in Enterococcus faecium by an active efflux pump mechanism. 38th ICAAC. San Diego, USA (1998) Abstract C–122.
   Google Scholar
• FRAIMOW H, KNOB C.: Amplification of macrolide efflux pumps msr and mef from Enterococcus faecium by polymerase chain reaction. 97th ASM General Meeting. Miami Beach, USA (1997) Abstract A–125.
   Google Scholar
• DENTS A, AGOURIDAS C, AUGER JM et al: Synthesis and antibacterial activity of HMR 3647 a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. Bioorg. Med. Chem. Lett. (1999) 9:3075–3080.
   PubMedGoogle Scholar
• ••Preparation of HMR-3647.
   Google Scholar
• MACGOWAN A.: Ketolides: a new class of antimicro-bial. Medical World Conference, Special CME Seminar, at 39th ICAAC. San Francisco, USA (September 26, 1999).
   Google Scholar
• ROBERTS MC: Telithromycin. Curr. Opin. Anti-infective Invest. Drugs (1999) 1:506–513.
   Google Scholar
• FLEMINGHAM D, CLARK S, ROBBINS MJ, DENCER C, BRYSKIER A: In vitro bactericidal activity of 11MR3647 respiratory tract pathogens. 39th ICAAC. San Diego, USA (1998) Absract E–133.
   Google Scholar
• HOELLMAN DB, UN G, BAJAKSOUZIAN S, JACOBS M, APPELBAUM PC: Activity of ABT-773 compared to other agents against pneumococci, Haemophilusinfluenzae and Moraxella catarrhalis. 39th ICAAC. San Francisco, USA (1999) Abstract F–2140.
   Google Scholar
• LENFANT B, SULTAN E, WABLE C, PASCUAL MH, MEYER BH, SCHOLTZ HE: Pharamacokinetics of 800 mg once-daily oral dosing of the ketolide, HMR 3647, in healthy young volunteers. 38th ICAAC. San Diego, USA (1998) Abstract A–49.
   Google Scholar
• DRUSANO G: Pharmacokinetics and pharmacody-namics of ketolides and the rationale for dosing. Medical World Conference, Special CME Seminar, at 39th ICAAC. San Francisco, USA (September 26, 1999).
   Google Scholar
• AGOURIDAS C, DENTS A, AUGER JM et al.: Synthesis and antibacterial activity of ketolides (6-0-methy1-3-oxoerythromycin derivatives): a new class of antibac-terials highly potent against macrolide-resistant and -susceptible respiratory pathogens. J. Med. Chem. (1998) 41:4080–4100.
   PubMed Web of Science ®Google Scholar
• ••Significant paper on ketolide chemistry and structure-activity relationships, the first paper on ketolide synthesis.
   Google Scholar
• VESGA O, BONNAT C, CRAIG WA: In vivo pharmacody- activity of HMR 3647, a new ketolide. 37th ICAAC. Toronto, Canada (1997) Abstract F–255.
   Google Scholar
• DENTS A, AGOURIDA C, BONNEFOY A, BRETIN F, FROMENTIN C, BONNET A: Synthesis and antibacterial activity of 2-halogen, 2-methyl and 2,3 enol-ether ketolides usingp-keto-ester chemistry. 39th ICAAC. San Francisco, USA (1999) Abstract F–2152.
   Google Scholar
• BONNEFOY A, DENTS A, BRETIN F, FROMENTIN C, AGOURIDAS C: In vitro antibacterial activity of two ketolides, HMR 3562 and HMR 3787 against respira-tory pathogens. 39th ICAAC. San Francisco, USA (1999) Abstract F–2155.
   Google Scholar
• BONNEFOY A, DENTS A, BRETIN F, FROMENTIN C, AGOURIDAS C: In vivo antibacterial activity of two ketolides, HMR 3562 and HMR 3787 highly active against respiratory pathogens. 39th ICAAC. San Francisco, USA (1999) Abstract F–2156.
   Google Scholar
• LEVASSEUR P, VALLEE E, BONNEFOY A et al.: Activity of ketolides HMR 3562 and HMR 3787 against erythromycin-sensitive (Ery-S) and -resistant (Ery-R) pneumococci in murine pneumonia models. 39th ICAAC. San Francisco, USA (1999) Abstract F–2158.
   Google Scholar
• PHAN L, OR YS, SPINA KP et al.: Tricyclic ketolides: mono-substitution on the imine ring. Synthesis and in vtiro antibacterial activity. 37th ICAAC. Toronto, Canada (1997) Abstract F–263.
   Google Scholar
• MA Z, CLARK RF, WANG S et al.: Design, synthesis and characterization of ABT-773: a novel ketolide highly active against multidrug resistant pathogens. 39th ICAAC. San Francisco, USA (1999) Abstract F–2133.
   Google Scholar
• ••Disclosure of ABT-773.
   Google Scholar
• SHORTRIDGE D, RAMER NC, BEYER J et al. The in vitro of ABT-773 against Gram-positive and-negative pathogens. 39th ICAAC. San Francisco, USA (1999) Abstract F–2136.
   Google Scholar
• BUT MH, ALMER LS, HENSEY DM et al: Antibacterial effects of ABT-773 against respiratory tract pathogens. 39th ICAAC. San Francisco, USA (1999) Abstract F–2138.
   Google Scholar
• MITTEN M, MEULBROEK J, PAIGE L et al: Efficacies of ABT-773 and HMR-3647 against respiratory pathogens causing acute systemic infections in mice and lung infections in rats. 39th ICAAC. San Francisco, USA (1999) Abstract F–2150.
   Google Scholar
• MEULBROEK J, MITTEN M, MOLLISON KW et al: Effica-cies of ABT-773 and azithromycin against experi-mental rat lung infections caused by Streptococcus pneumoniae. 39th ICAAC. San Francisco, USA (1999) Abstract F–2151.
   Google Scholar
• HERNANDEZ L, SADRZADEH N, KRILL S, MA Z, MARSH K.: Preclinical pharmacokinetic profile of ABT-773 in mouse, rat, monkey and dog. 39th ICAAC. San Francisco, USA (1999) Abstract F–2148.
   Google Scholar
• GUAN Z, JAYANTI V, JOHNSON M et al.: In vitro and in vivo metabolism of [14C]ABT-773. 39th ICAAC. San Francisco, USA (1999) Abstract F–2149.
   Google Scholar
• PHAN LT, OR YS, CHEN Y et al.: 2-Substituted tricyclic ketolides: new antibacterial macrolides - synthesis and biological activity. 38th ICAAC. San Diego, USA (1998) Abstract F–127.
   Google Scholar
• •Improved activity of C-2 fluorinated ketolides.
   Google Scholar
• ELLIOTT RL, PIREH D, GRIESGRABER G et al.: Anhydrolide macrolides. 1. Synthesis and antibacte-rial activity of 2,3- anhydro-6-0-methyl 11,12-carbamate erythromycin A analogues. J. Med. Chem. (1998) 41:1651–1659.
   Google Scholar
• MA Z, OR YS, CLARK RF et al: Synthesis and antibacterial activity of 6-0-substituted ketolides. 38th ICAAC. San Diego, USA (1998) Abstract F–126.
   Google Scholar
• ASAKA T, KASHIMURA M, MANAKA A et al: Structure activity studies leading potent acylides: 3-0-acy1-5-0-desoaminylerythronolide 11,12-carbamates. 39th ICAAC. San Francisco, USA (1999) Abstract F–2159.
   Google Scholar
• ASAKA T, KASHIMURA M, TANIKAWA T et al: New macrolide antibiotics. Acylides (3-0-acy1-5-desosaminylerythronolides); synthesis and biological properties. 37th ICAAC. Toronto, Canada (1997) Abstract F–262.
   Google Scholar
• ASAKA T, KASIMURA M, TANIKAWA T et al: Synthesisand antibacterial activities of unique acylides: 3-0-acy1-5- 0-desosaminylerthronolide 6,9;11,12-dicarbonates. 39th ICAAC. San Francisco, USA (1999) Abstract F–2159.
   Google Scholar
• WADDELL ST, SANTORELLI GM, BLIZZARD TA, GRAHAMA, OCCI J: Synthesis and antibacterial activity of 0-methyl derivatives of azalide antibiotics: II. 6-0ME derivatives via clarithromycin. Bioorg. Med. Chem. Lett. (1998) 8:1321–1326.
   Google Scholar
• LOPOTAR N, NARANDA A, VELA V, DEREK M, MARSIC N:Synthesis and microbiological assay of 17-membered azalides. Proceedings of the Fifth International Conference the Macrolides, Azalides, Streptogramins, Ketolides and. Seville, Spain (2000) Abstract 01.01.
   Google Scholar
• DENTS A, AGOURIDAS C: Synthesis of 6-0-methyl-azithromycin and its ketolide analogue via Beckmann rearrangement of 9(E)-6-0-methyl-erythromycin oxime. Bioorg. Med. Chem. Lett. (1998) 8:2427–2432.
   PubMed Web of Science ®Google Scholar
• SU W: Novel macrolide C-4' carbamate derivatives. 3rd International Antibacterial Drug Discovery. Princeton, USA (1998).
   Google Scholar
• WU YJ, WONS R, DURKIN D et al.: Synthesis and in vitro activity of novel C-4' carbamate derivatives of 14- and 15-membered macrolides. 38th ICAAC. San Diego, USA (1998) Abstract F–123.
   Google Scholar
• SU WG, SMYTH KT, RAINVILLE JP et al.: Novel erythro-mycyclamine 4-carbamate antibacterial agents: synthesis and biological evaluation resulting in discovery of CP-544372. 38th ICAAC. San Diego, USA (1998) Abstract F–122.
   Google Scholar
• BRENNAN L, DUIGNAN J, PETITPAS J et al.: CP-544372: MIC90 studies and killing kinetics against key respira-tory tract pathogens. 38th ICAAC. San Diego, USA (1998) Abstract F–124.
   Google Scholar
• GIRARD D, MATHIEU HVV, GIRARD AE et al.: In vivo oralefficacy of CP-544,372, a new erythromycyclamine C4 carbamate, against macrolide-resistant pneumococci and Haemophilus influenzae. 38th ICAAC. San Diego, USA (1998) Abstract F–121.
   Google Scholar
• GIRARD D, MATHIEU HVV, GIRARD AE et al.: Pharmacoki-netics and pharmacodynamics of CP-544,372, a new erythromycylamine C4 carbamate, in murine pneumococcal pulmonary infections. 38th ICAAC. San Diego, USA (1998) Abstract F–120.
   Google Scholar
• KU YY, RILEY D, GRIEME T, NILIUS A: Synthesis and antibacterial activities of novel 12-0-methyl erythro-mycin A derivatives. J. Antibiot. (Tokyo) (1999) 52:908–912.
   PubMedGoogle Scholar
• MINICH ML, LUNDY KM, RAFKA RJ, MORTON BJ: Azalide3,6-ket als: discovery of a novel class of azalide antibi-otics. 218th ACS National Meeting - Division of Organic Chemistry. New Orleans, USA (1999) Abstract 583.
   Google Scholar
• MINICH ML LUNDY KM: Structural elucidation ofdescladinose azithromycin-3,6-(4-azacyclohexy0 ket al by 1-and 2-D NMR spectroscopy. 218th ACS National Meeting - Division of Organic Chemistry. New Orleans, USA (1999) Abstract 570.
   Google Scholar
• TSUZUKI K, SUNAZUKA T, MARUI S et al.: Motilides, macrolides with gastrointestinal motor stimulating activity. I. 0-substituted and tertiary N-substituted derivatives of 8,9-anhydroerythromycin A 6,9-hemiacet al. Chem. Pharm. Bull. (Tokyo) (1989) 37:2687–2700.
   Google Scholar
• FAGHIH R, LARTEY PA, NELLANS HN et al.: Synthesis of 9-deoxo-4"-deoxy-6,9-epoxyerythromycin deriva-tives: novel and acid-stable motilides. J. Med. Chem. (1998) 41:3402–3408.
   PubMedGoogle Scholar
• FAGHIH R, EDWARDS CM, FREIBERG L, NELLANS H: Entry into erythromycin lactams: synthesis of A lactam enol ether as a potential gastrointes-tinal prokinetic agent. SYNLET7' (1998):751–753.
   Google Scholar
• LABRO MT: Anti-inflammatory activity of macrolides: a new therapeutic potential? J. Antimicrob. Chemother. (1998) 41 (Suppl.B):37–46.
   Google Scholar
• •Review on anti-inflammatory activity of macrolides.
   Google Scholar
• SUNAZUKA T, TAKIZAWA H, DESAKI M et al.: Effects of erythromycin and its derivatives on interleukin-8 release by human bronchial epithelial cell line BEAS-2B cells. J. Antibiot. (Tokyo) (1999) 52:71–74.
   PubMed Web of Science ®Google Scholar
• JAFFE A, FRANCIS J, ROSENTHAL M, BUSH A: Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet (1998) 351:420.
   PubMed Web of Science ®Google Scholar
• SAKITO O, KADOTA J, KOHNO S et al: Interleukin 1 beta, tumor necrosis factor alpha and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration (1996) 63:42–48.
   PubMed Web of Science ®Google Scholar
• ABE S, NAKAMURA H, INOUE S et al.: Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. (2000) 22:51–60.
   PubMedGoogle Scholar
• SAIKKU P, LEINONEN M, TENKANEN L et al.: Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann. Intern. Med. (1992) 116:273–278.
   PubMed Web of Science ®Google Scholar
• THOM DH, GRAYSTON JT, SISCOVICK DS et al: Associa-tion of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. J. Am. Med. Assoc. (1992) 268:68–72.
   PubMed Web of Science ®Google Scholar
• MELNICK SL, SHAHAR E, FOLSOM AR et al.: Past infection by Chlamydia pneumoniae strain TWAR and asympto-matic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am. J. Med. (1993) 95:499–504.
   Google Scholar
• GRAYSTON JT, KUO CC, COULSON AS et al.: Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation (1995) 92:3397–3400.
   PubMed Web of Science ®Google Scholar
• HAMADA K, KITA E, SAWAKI M, MIKASA K, NARITA N: Antitumor effect of erythromycin in mice. Chemotherapy (1995) 41:59–69.
   PubMedGoogle Scholar
• HAMADA K, MIKASA K, YUNOU Y et al.: Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. Chemotherapy (2000) 46:49–61.
   PubMedGoogle Scholar
• YATSUNAMI J, FUKUNO Y, NAGATA M et al.: Antiangio-genic and antitumor effects of 14-membered ring macrolides on mouse B16 melanoma cells. Clin. Exp. Metastasis (1999) 17:361–367.
   PubMed Web of Science ®Google Scholar
• YATSUNAMI J, TSURUTA N, FUKUNO Y et al.: Inhibitory effects of roxithromycin on tumor angiogenesis, growth and metastasis of mouse B16 melanoma cells. Clin. Exp. Metastasis (1999) 17:119–124.
   PubMed Web of Science ®Google Scholar
• CANE DE, WALSH CT: The parallel and convergent universes of polyketide synthases and nonribosomal peptide synthetases. Chem. Biol. (1999) 6:R319–325.
   PubMed Web of Science ®Google Scholar
• CORTES J, HAYDOCK SF, ROBERTS GA, BEVITT DJ, LEADLAY PF: An unusually large multifunctional polypeptide in the erythromycin- producing polyketide synthase of Saccharopolyspora mythraea. Nature (1990) 348:176–178.
   PubMed Web of Science ®Google Scholar
• ••First disclosures of modular nature of Type I PKS.
   Google Scholar
• DONADIO S, STAVER MJ, MCALPINE JB, SWANSON SJ, KATZ L: Modular organization of genes required for complex polyketide biosynthesis. Science (1991) 252:675–679.
   PubMed Web of Science ®Google Scholar
• ••First successful PKS manipulation.
   Google Scholar
• DONADIO S, MCALPINE JB, SHELDON PJ, JACKSON M, KATZ L: An erythromycin analog produced by reprogramming of polyketide synthesis. Proc. Natl. Acad. Sci. USA (1993) 90:7119–7123.
   PubMed Web of Science ®Google Scholar
• KAKAVAS SJ, KATZ L, STASSI D: Identification and characterization of the niddamycin polyketide synthase genes from Streptomyces caelestis. J. Bacteriol. (1997) 179:7515–7522.
   PubMedGoogle Scholar
• SWAN DG, RODRIGUEZ AM, VILCHES C, MENDEZ C, SALAS JA: Characterisation of a Streptomyces antibi-oticus gene encoding a Type I polyketide synthase which has an unusual coding sequence. Mol. Gen. Genet. (1994) 242:358–362.
   PubMedGoogle Scholar
• XUE Y, SHERMAN DH: Alternative modular polyketide synthase expression controls macrolactone structure. Nature (London) (2000) 403:571–575.
   PubMed Web of Science ®Google Scholar
• •Selective control of biosynthesis of 12- or 14-membered macrolides.
   Google Scholar
• APARICIO JF, MOLNAR I, SCHWECKE T et al.: Organiza-tion of the biosynthetic gene cluster for rapamycin in Streptomyces hygroscopicus: analysis of the enzymatic domains in the modular polyketide synthase. Gene (1996) 169:9–16.
   PubMed Web of Science ®Google Scholar
• MOTAMEDI H, SHAFIEE A: The biosynthetic gene cluster for the macrolactone ring of the immunosup-pressant FK506. Eur. J. Biochem. (1998) 256:528–534.
   PubMedGoogle Scholar
• SCHUPP T, TOUPET C, ENGEL N, GOFF S: Cloning and sequence analysis of the putative rifamycin polyketide synthase gene cluster from Amycolatopsis mediter-ranei. FEMS Microbiol. Lett. (1998) 159:201–207.
   PubMedGoogle Scholar
• IKEDA H, NONOMIYA T, USAMI M, OHTA T, OMURA S: Organization of the biosynthetic gene cluster for the polyketide antihelmintic macrolide avermectin in Streptomyces avermitilis. Proc. Natl. Acad. Sci. USA (1999) 96:9509–9514.
   PubMed Web of Science ®Google Scholar
• MACNEIL DJ, OCCI JL, GEWAIN K, MMACNEIL T: Correla-tion of the avermectin polyketide synthase genes to the avermectin structure. Implications for designing novel avermectins. Ann. NY Acad. Sci. (1994) 721:123–132.
   PubMed Web of Science ®Google Scholar
• CORTES J, WIESMANN KE, ROBERTS GA et al.: Reposi-tioning of a domain in a modular polyketide synthase to promote specific chain cleavage. Science (1995) 268:1487–1489.
   PubMed Web of Science ®Google Scholar
• BROWN MJB, CORTES J, CUTTER AL, LEADLAY PF, STAUNTON J: A mutant generated by expression of an engineered DEBS1 protein from the erythromycin- polyketide synthase (PKS) in Streptomyces coelicolor produces the triketide as a lactone, but the major product is the nor-analog derived from acetate as starter acid. J. Chem. Soc., Chem. Commun. (1995):1517–1518.
   Google Scholar
• WIESMANN KE, CORTES J, BROWN MJ et al.: Polyketide synthesis in vitro on a modular polyketide synthase. Chem. Biol. (1995) 2:583–589.
   PubMedGoogle Scholar
• OLIYNYK M, BROWN MJ, CORTES J, STAUNTON J, LEADLAY PF: A hybrid modular polyketide synthase obtained by domain swapping. Chem. Biol. (1996) 3:833–839.
   PubMedGoogle Scholar
• ••Targeted generation of novel triketide lactone throughdomain exchange.
   Google Scholar
• BOHM I, HOLZBAUR IE, HANEFELD U et al.: Engineering of a minimal modular polyketide synthase and targeted alteration of the stereospecificity of polyketide chain extension. Chem. Biol. (1998) 5:407–412.
   PubMedGoogle Scholar
• WEISSMAN KJ, BYCROFT M, STAUNTON J, LEADLAY PF: Origin of starter units for erythromycin biosynthesis. Biochemistry (1998) 37:11012–11017.
   PubMedGoogle Scholar
• KAO CM, LUO G, KATZ L, CANE DE, KHOSLA C: Engineered biosynthesis of a triketide lactone from an incomplete modular polyketide synthase. J. Am. Chem. Soc. (1994) 116:11612–11613.
   Web of Science ®Google Scholar
• PIEPER R, LUO G, CANE DE, KHOSLA C: Remarkably broad substrate specificity of a modular polyketide synthase in a cell-free system. J. Am. Chem. Soc. (1995) 117: 11373–11374.
   Google Scholar
• PIEPER R, EBERT-KHOSLA S, CANE D, KHOSLA C: Erythromycin biosynthesis: kinetic studies on a fully active modular polyketide synthase using natural and unnatural substrates. Biochemistry (1996) 35:2054–2060.
   PubMedGoogle Scholar
• KAO CM, LUO G, KATZ L, CANE DE, KHOSLA C: Engineered biosynthesis of structurally diverse tetraketides by a trimodular polyketide synthase. J. Am. Chem. Soc. (1996) 118:9184–9185.
   Web of Science ®Google Scholar
• BEDFORD D, JACOBSEN JR, LUO G, CANE DE, KHOSLA C: A functional chimeric modular polyketide synthase generated via domain replacement. Chem. Biol. (1996) 3:827–831.
   PubMed Web of Science ®Google Scholar
• PIEPER R, GOKHALE RS, LUO G, CANE DE, KHOSLA C: Purification and characterization of bimodular and trimodular derivatives of the erythromycin polyketide synthase. Biochemistry (1997) 36:1846–1851.
   PubMedGoogle Scholar
• CANE DE, CELMER WD, WESTLEY JW: Unified stereo-chemical model of polyether antibiotic structure and biogenesis. J. Am. Chem. Soc. (1983) 105:3594–3600.
   Web of Science ®Google Scholar
• HOLZBAUR IE, HARRIS RC, BYCROFT M et al.: Molecular basis of Celmer's rules: the role of two ketoreductase domains in the control of chirality by the erythro-mycin modular polyketide synthase. Chem. Biol. (1999) 6:189–195.
   PubMedGoogle Scholar
• WEISSMAN KJ, TIMONEY M, BYCROFT M et al: The molecular basis of Celmer's rules: the stereochemistry of the condensation step in chain extension on the polyketide synthase. Biochemistry (1997) 36:13849–13855.
   PubMedGoogle Scholar
• CANE DE, LUO G, KHOSLA C, KAO CM, KATZ L: Erythro-mycin biosynthesis. Highly efficient incorporation of polyketide chain elongation intermediates into 6-deoxyerythronolide B in an engineered Strepto-myces host. J. Antibiot. (Tokyo) (1995) 48:647–651.
   Google Scholar
• KAO CM, KATZ L, KHOSLA C: Engineered biosynthesis of a complete macrolactone in a heterologous host. Science (1994) 265:509–512.
   PubMed Web of Science ®Google Scholar
• ••Expression of erythromycin lactone in S. coelicolor.
   Google Scholar
• KAO CM, LUO G, KATZ L, CANE DE, KHOSLA C: Manipu-lation of macrolide ring size by directed mutagenesis of a modular polyketide synthase. J. Am. Chem. Soc. (1995) 117:9105–9106.
   Web of Science ®Google Scholar
• PIEPER R, LUO G, CANE DE, KHOSLA C: Cell-free synthesis of polyketides by recombinant erythro-mycin polyketide synthases. Nature (1995) 378:263–266.
   PubMedGoogle Scholar
• MCDANIEL R, KAO CM, FU H et al: Gain-of-function mutagenesis of a modular polyketide synthase. J. Am. Chem. Soc. (1997) 119:4309–4310.
   Web of Science ®Google Scholar
• KAO CM, MCPHERSON M, MCDANIEL RN et al.: Gain of function mutagenesis of the erythromycin polyketide synthase. 2. Engineered biosynthesis of an eight-membered ring tetraketide lactone. J. Am. Chem. Soc. 119:11339–11340.
   Google Scholar
• MCDANIEL R, THAMCHAIPENET A, GUSTAFSSON C et al.: Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel 'unnatural' natural products. Proc. Natl. Acad. ScL USA (1999) 96:1846–1851.
   PubMed Web of Science ®Google Scholar
• •Library approach to combinatorial biosynthesis.
   Google Scholar
• KUHSTOSS S, HUBER M, TURNER JR, PASCHAL JW, RAO RN: Production of a novel polyketide through the construction of a hybrid polyketide synthase. Gene (1996) 183:231–236.
   PubMed Web of Science ®Google Scholar
• ••Novel polyketide through heterologous modulesubstitution.
   Google Scholar
• MCARTHUR, HAI: The novel avermectin, doramectin - a successful application of mutasynthesis. Dev. Ind. Microbiol. (1997) 35:43–48.
   Google Scholar
• MARSDEN AF, WILKINSON B, CORTES J et al.: Engineering broader specificity into an antibiotic-producing polyketide synthase. Science (1998) 279:199–202.
   PubMed Web of Science ®Google Scholar
• PACEY MS, DIRLAM JP, GELDART RW et al.: Novel erythromycins from a recombinant Saccharopoly-spora mythraea strain NRRL 2338 pIG1. I. Fermenta-tion, isolation and biological activity. J. Antibiot. (Tokyo) (1998) 51:1029–1034.
   PubMed Web of Science ®Google Scholar
• ••Novel erythromycins through loading domain substitution.
   Google Scholar
• PARSONS IC, EVERETT JR, PACEY MS et al.: Structural elucidation of a novel erythromycin, 13-cyclopentyl-13-desethyl-erythromycin B, from a recombinant Saccharopolyspora erythraea strain, NRRL 2338 pIG/1. J. Antibiot. (Tokyo) (1999) 52:190–192.
   PubMedGoogle Scholar
• BROWN MS, DIRLAM JP, MCARTHUR HA et al: Produc-tion of 6-deoxy-13-cyclopropyl-erythromycin B by Saccharopolyspora mythraeaNRRL 18643.1 Antibiot. (Tokyo) (1999) 52:742–747.
   Google Scholar
• LUO G, PIEPER R, ROSA A, KHOSLA C, CANE DE: Erythro-mycin biosynthesis: exploiting the catalytic versatility of the modular polyketide synthase. Bioorg. Med. Chem. (1996) 4:995–999.
   PubMedGoogle Scholar
• CANE DE, PRABHAKARAN PC, TAN W, OTT WR: Macrolide biosynthesis. 6. Mechanism of polyketide chain elongation. Tetrahedron Lett. (1991) 32:5457–5460.
   Google Scholar
• YUE S, DUCAN JS, YAMAMOTO Y, HUTCHINSON CR: Macrolide biosynthesis. Tylactone formation involves the processive addition of three carbon units. J. Am. Chem. Soc. (1987) 109:1253–1255.
   Google Scholar
• CANE DE, YANG C-C: Macrolide biosynthesis. 4. Intact incorporation of a chain-alongation intermediate into erythromycin. J. Am. Chem. Soc. (1987) 109:1255–1257.
   Google Scholar
• CANE DE, LAMBALOT RH, PRABHAKARAN PC, OTT WR: Macrolide biosynthesis. 7. Incorporation of polyketide chain elongation intermediates into methymycin. J. Am. Chem. Soc. (1993) 115:522–526.
   Google Scholar
• CANE DE, TAN W, OTT WR: Nargenicin biosynthesis. Incorporation of polyketide chain elongation intermediates and support for a proposed intramol-ecular Diels-Alder cyclization. J. Am. Chem. Soc. (1993) 115:527–535.
   Google Scholar
• DUTTON CJ, HOOPER AM, LEADLAY PF, STAUNTON J: Avermectin biosynthesis. Intact incorporation of a diketide chain-assembly intermediate into the polyketide macrocyclic ring. Tetrahedron Lett. (1994) 35:327–330.
   Google Scholar
• LESS SL, HANDA S, LEADLAY PF, DUTTON CJ, STAUNTON J: Biosynthesis of tetronasin: Part 5. Novel fluorinated and non-fluorinated analogs of tetronasin via intact incorporation of di-, tri- and tetraketide analog precur-sors. Tetrahedron Lett. (1996) 37:3511–3514.
   Google Scholar
• JACOBSEN JR, HUTCHINSON CR, CANE DE, KHOSLA C: Precursor-directed biosynthesis of erythromycin analogs by an engineered polyketide synthase. Science (1997) 277:367–369.
   PubMed Web of Science ®Google Scholar
• JACOBSEN JR, KEATINGE-CLAY AT, CANE DE, KHOSLA C: Precursor-directed biosynthesis of 12-ethyl erythro-mycin. Bioorg. Merl. Chem. (1998) 6:1171–1177.
   PubMedGoogle Scholar
• POHL NL, GOKHALE RS, CANE DE, KHOSLA C: Synthesis and incorporation of an N-acetylcysteamine analog of methylmalonyl-CoA by a modular polyketide synthase. J. Am. Chem. Soc. (1998) 120:11206–11207.
   Google Scholar
• BISANG C, LONG PF, CORTES J et al: A chain initiation factor common to both modular and aromatic polyketide synthases. Nature (1999) 401:502–505.
   PubMed Web of Science ®Google Scholar
• ••Elucidation of KSQ mechanism.
   Google Scholar
• HUTCHINSON CR, FUJII I: Polyketide synthase gene manipulation: a structure-function approach in engineering novel antibiotics. Ann. Rev. Microbiol. (1995) 49:201–238.
   PubMed Web of Science ®Google Scholar
• BETLACH MC, KEALEY JT, ASHLEY GW, MCDANIEL R: Characterization of the macrolide P-450 hydroxylase from Streptomyces venezuelae which converts narbomycin to picromycin. Biochemistry (1998) 37:14937–14942.
   PubMedGoogle Scholar
• BALTZ RH: New genetic methods to improve secondary metabolite production in Streptomyces. J. Ind. Microbiol. Biotechnol. (1998) 20:360–363.
   Web of Science ®Google Scholar
• SALAH-BEY K, DOUMITH M, MICHEL JM et al.: Targeted gene inactivation for the elucidation of deoxysugar biosynthesis in the erythromycin producer Saccharo-polyspora erythraea. Mol. Gem Genet. (1998) 257:542–553.
   PubMedGoogle Scholar
• •Novel erythromycin through manipulation of sugar genes.
   Google Scholar
• GAISSER S, BOHM GA, DOUMITH M et al: Analysis of eryBI, eryBIII and eryBVII from the erythromycin biosynthetic gene cluster in Saccharopolyspora mythraea. Mol. Gen. Genet. (1998) 258:78–88.
   PubMedGoogle Scholar
• BORISOVA SA, ZHAO L, SHERMAN DH, LIU H-W: Biosyn-thesis of desosamine: construction of a new macrolide carrying a genetically designed sugar moiety. Org. Lett. (1999) 1:133–136.
   PubMedGoogle Scholar
• ZHAO L, AHLERT J, XUE Y et al.: Engineering a methymycin/pikromycin-calicheamicin hybrid: Construction of two new macrolides carrying a designed sugar moiety. J. Am. Chem. Soc. (1999) 121:9881–9882.
   Google Scholar